BioTuesdays
PDS Biotechnology Logo

PDS launches Phase 3 trial for HNSCC

PDS Biotechnology (NASDAQ:PDSB) announced that it has commenced its Phase 3 trial, VERSATILE-003, to evaluate the efficacy and safety of Versamune HPV plus pembrolizumab for head and neck squamous cell carcinoma (HNSCC)...